10-K/A: SS Innovations International Restates 2022 and 2023 Financials Following Accounting Errors and Auditor Change

SS Innovations International has restated its financial statements for 2022 and 2023 due to material accounting errors and a change in auditors, revealing ineffective internal controls.

Summary

• SS Innovations International has filed an amendment to its annual report, restating its consolidated financial statements for the years ended December 31, 2023, and 2022.
• The restatement was prompted by the dismissal of their previous auditor, BF Borgers CPA PC, and the subsequent engagement of BDO India LLP, which led to a re-audit and internal review.
• The company discovered material errors in the previously issued financial statements, including issues with accounting for the merger transaction, revenue recognition for deferred payment sales, and the recognition of right-of-use assets and lease liabilities.
• As a result, management concluded that the company's disclosure controls and procedures and internal controls over financial reporting were not effective as of December 31, 2023, due to material weaknesses.
• The company sold 12 surgical robotic systems in 2023, compared to 3 in 2022, and installed an additional 7 systems for clinical evaluation or on a pay-per-use basis.
• Total revenue for 2023 was $5,875,314, a significant increase from $1,436,147 in 2022.
• The company reported a net loss of $20,878,292 for 2023, compared to a net loss of $3,213,882 in 2022, primarily due to increased stock compensation and general and administrative expenses.
• The company had a working capital surplus of $12,954,941 as of December 31, 2023, compared to a working capital deficit of $3,670,953 as of December 31, 2022.
• The company plans to raise additional capital through private or public offerings in 2024.

Sentiment

Score: 4

Explanation: The document reveals significant financial and operational challenges, including a large net loss, material weaknesses in internal controls, and a restatement of financials. While revenue growth is positive, the overall sentiment is negative due to the company's financial instability and dependence on future funding.

Positives

• The company's revenue increased significantly year-over-year, driven by increased sales of surgical robotic systems and instruments.
• The company successfully converted a significant amount of debt into equity, improving its working capital position.
• The company has a growing number of installed systems, including those for clinical evaluation and pay-per-use.
• The company has a strong focus on research and development to improve its existing system and expand its product offerings.

Negatives

• The company experienced a substantial net loss in 2023, primarily due to increased stock compensation and general and administrative expenses.
• The company identified material weaknesses in its internal control over financial reporting.
• The company's previous auditor was barred from appearing before the SEC.
• The company is dependent on further funding to meet its obligations and sustain operations.
• The company has not yet established consistent operational revenue cash flows to meet all its fixed operating costs.

Risks

• The company's ability to continue as a going concern is dependent on securing additional financing.
• The company faces risks related to obtaining regulatory approvals in various markets.
• The company's financial performance is dependent on increasing awareness of robotically assisted surgery and market acceptance of its systems.
• The company is involved in litigation regarding a disputed shareholding in a subsidiary.
• The company's internal controls over financial reporting were deemed ineffective due to material weaknesses.

Future Outlook

The company expects to require substantial funds for scaling up operations, incurring capital expenditures, and continuing research and development. They plan to raise additional capital through further private or public offerings in 2024. However, there is no assurance that they will be able to secure additional funding.

Management Comments

• Management has re-evaluated the effectiveness of SSis disclosure controls and procedures and internal control over financial reporting as of December 31, 2023.
• Management has concluded that SSis disclosure controls and procedures and internal controls over financial reporting were not effective as of December 31, 2023, due to material weaknesses.
• Management is addressing and remediating these material weaknesses with the support and assistance of the accounting and financial staff employed by our Indian operating subsidiary.
• Management believes that it will be successful in obtaining the necessary financing to fund our operations going forward.

Industry Context

The company operates in the surgical robotics industry, which is experiencing increasing recognition of robotically assisted surgeries as an approved treatment modality. The company's manufacturing operations in India provide cost advantages, which could help them compete in the market. However, the company's financial performance is also dependent on obtaining regulatory approvals in various regulated markets.

Comparison to Industry Standards

• The company's revenue growth from $1.4 million to $5.8 million year-over-year indicates a strong demand for their surgical robotic systems, but the significant increase in net loss to $20.8 million highlights the challenges in scaling operations while managing costs.
• Compared to established players like Intuitive Surgical (ISRG), which has a much larger revenue base and consistent profitability, SS Innovations is still in a high-growth, high-risk phase.
• Companies like Stryker (SYK) and Medtronic (MDT) also have significant presence in the surgical robotics market, but they have diversified product portfolios and established distribution networks, which SS Innovations is still developing.
• The company's reliance on private funding and convertible notes is typical for early-stage companies in this sector, but it also introduces risks related to dilution and debt obligations.
• The restatement of financials and identification of material weaknesses in internal controls are concerning and highlight the need for improved financial management and governance, which is a common challenge for rapidly growing companies.

Corporate Governance

Legal Proceedings

• In April 2024, an ex-shareholder of Otto Pvt Ltd. commenced litigation in the Bahamas, seeking legal confirmation that it holds 9,000 shares (approximately a 9% interest) in Otto.
• Dr. Srivastava and Otto have filed an action in the Bahamas to confirm the cancellation of the shares and reconfirm their ownership.
• The Bahamian court has issued an interim order to maintain the status quo with respect to the disputed shares and Ottos shareholdings in Sudhir Srivastava Innovations Pvt Ltd.

Related Party Transactions

• As of December 31, 2023, there was $1,567,559 in net amounts due from related parties.
• On April 15, 2023, the company executed a Line of Credit Note with Sushruta Pvt Ltd., which was later converted into shares.
• The company sold two surgical robotic systems to Aster Hospitals Group, where a director of the company holds a key position.
• The company has sold $2,450,000 in principal amount of 7% Convertible One-Year Promissory Notes to five investors, one of whom was Sushruta, who subscribed for a $1,000,000 Bridge Note.
• In April 2024, the Company raised $2,000,000 from Sushruta Pvt Ltd. by issuance of two 7% One-Year Promissory note of $ 1,000,000 each.
• In July 2024, the Company further raised $500,000 from Sushruta Pvt Ltd. by issuance of another One-Year 7% One-Year Promissory notes.
• In October 2024, the Company borrowed $250,000 from Sushruta Pvt Ltd. to meet certain working capital needs evidenced by an additional One-Year 7% Promissory Note.

Stakeholder Impact

• Shareholders may experience dilution due to potential capital raises.
• Employees may be affected by the company's financial instability and potential restructuring.
• Customers may be concerned about the company's ability to provide ongoing support and maintenance.
• Suppliers may face increased credit risk due to the company's financial challenges.
• Creditors may be concerned about the company's ability to repay its debts.

Next Steps

• The company will continue to address and remediate the identified material weaknesses in internal controls.
• The company will implement a new ERP system to integrate all business functions within the accounting and financial department.
• The company plans to raise additional capital through private or public offerings.
• The company will continue to focus on scaling up operations and expanding its product offerings.

Key Dates

Keywords

surgical robotics, financial restatement, internal controls, revenue growth, net loss, capital raise, auditor change, material weaknesses, SSi Mantra, medical devices